Our Anti-Vimentin primary antibody from PhosphoSolutions is chicken polyclonal. It detects human, mouse, and rat Vimentin and is total IgY fraction. It is great for use in WB, IHC, ICC.
Primary Antibody
Bovine, Human, Mouse, Rat
Bovine, Canine, Feline, Goat, Guinea Pig, Hamster, Horse, Non-Human Primate, Rabbit, Sheep, Vole
ICC, IHC, WB
Chicken
Total IgY fraction
VIM
50 kDa











Immunostaining of tumors and precursor PanIN lesions from 4 week old LSL-KrasG12D; Cdkn2alox/lox; p48Cre (KIC) mice that were treated with 2G8 and/or gemcitabine, Gem. (Anti-Vimentin, cat. 2105-VIM, green; Anti-E-cadherin, red). Photo courtesy of Rolf Brekken, University of Texas Southwestern. CC-BY-4.0
Product Specific References for Applications and Species
- Immunohistochemistry: Mouse
Immunohistochemistry: Mouse | ||
PMID | Dilution | Publication |
26206560 | not listed | Kirane, A., et al. 2015. Warfarin blocks Gas6-mediated Axl activation required for pancreatic cancer epithelial plasticity and metastasis. Cancer Research, 75(18), pp.3699-3705. |
25060520 | not listed | Ostapoff, K. T., et al. 2014. Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis. Cancer Research, 74(18), 4996-5007. |
23696215 | not listed | Ostapoff, K. T., et al. 2013. PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer. Molecular Cancer Therapeutics, 12(7), pp.1190-1201. |
22829202 | not listed | Kirane, A., et al. 2012. Apricoxib, a novel inhibitor of COX-2, markedly improves standard therapy response in molecularly defined models of pancreatic cancer. Clinical Cancer Research, 18(18), pp.5031-5042 |
22678114 | not listed | Kirane, A., et al. 2012. Epithelial-mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib. Carcinogenesis, 33(9), 1639-46. |